LncRNA FEZF1-AS1 regulates the gene expression and alternative splicing associated with osteosarcoma

  • J Orthop Surg Res. 2025 Dec 3;21(1):24. doi: 10.1186/s13018-025-06357-z.
Yanlong Han  #  1 ,  Ziang Ye  #  1 ,  Li Wang  2
Affiliations
  • 1. Department of Bone and Joint Surgery Center, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, 830001, China.
  • 2. Department of Bone and Joint Surgery Center, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, 830001, China. [email protected].
  • # Contributed equally.
PMID: 41331461 DOI: 10.1186/s13018-025-06357-z
Abstract

Background: Osteosarcoma (OS) faces a high metastatic burden, limited effective treatments, and a lack of specific therapeutic targets.

Methods: In this prospective study, we established a human osteosarcoma cell (HOS) model overexpressing lncRNA FEZF1-AS1 (OE FEZF1-AS1), and subsequently obtained FEZF1-AS1-affected transcriptome data using high-throughput RNA Sequencing (RNA-seq).

Results: OE FEZF1-AS1 promoted HOS cell proliferation and invasion, upregulated 125 genes, suppressed 48 genes, and impacted 1156 alternative splicing events (ASEs), including pathways like C-type lectin receptor signaling and Yersinia pestis Infection.

Conclusions: LncRNA FEZF1-AS1 plays a pivotal role in promoting the proliferation and invasion of HOS cells. Moreover, our study provides a comprehensive gene screening approach for identifying potential targets of FEZF1-AS1, emphasizing their regulatory mechanisms and ASEs in OS.

Keywords
Alternative Splicing; LncRNA FEZF1-AS1; Osteosarcoma; RNA Sequencing.
Products